Photo from wikipedia
With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH… Click to show full abstract
With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH may progress to cirrhosis and hepatocellular carcinoma. Currently, no treatment is available for NASH. Therefore, finding a therapy for NAFLD/NASH is in urgent need. Previously we have demonstrated that mice lacking CD47 or its ligand thrombospondin1 (TSP1) are protected from obesity‐associated NALFD. This suggests that CD47 blockade might be a novel treatment for obesity‐associated metabolic disease. Thus, in this study, the therapeutic potential of an anti‐CD47 antibody in NAFLD progression was determined.
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!